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The work carried in the research tenure has been compiled in the form of a thesis 
entitled “Synthesis and biological evaluation of new pyrrolobenzodiazepines, 
tetrazoles and quinazolinone derivatives as potential anticancer agents”. The main 
aim of this work is the design and synthesis of diaryl ether linked pyrrolobenzo-
diazepine conjugates, to explore their DNA binding ability as well as anticancer 
activity and synthesis of tetrazolo linked isoxazoline/cinnamide hybrids, to 
investigate their anticancer activity and inhibition of tubulin polymerization. Further, 
chalcone linked quinazolinone hybrids has been prepared and evaluated for their 
anticancer activity. The thesis has been divided into four chapters.   
 CHAPTER I: This chapter gives the general introduction about cancer 
chemotherapy, covalent interactions of drug-DNA, particularly of pyrrolo[2,1-c]-
[1,4]benzodiazepine (PBD) antitumor antibiotics, combretastatins, quinazolinones 
and the objectives of the present work. 
 CHAPTER II: This chapter describes the synthesis of diaryl ether-PBD conjugates 
linked through five carbon spacer or a piperazine and evaluation of their 
anticancer activity against a panel of eleven human cancer cell lines, and also 
discussed the DNA-binding ability. 
 CHAPTER III: This chapter deals with the synthesis and biological evaluation of 
new tetrazole linked isoxazoline/cinnamide hybrids as potential anticancer agents. 
Further, the effect of these compounds on cell cycle and inhibition of tubulin 
polymerization has been studied.  
 CHAPTER IV: This chapter illustrates the design, synthesis and biological 
evaluation of new chalcone linked quinazolinone hybrids as potential anticancer 
agents. 
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This chapter describes the general introduction about pyrrolobenzodiazepines, 
combretastatins, quinazolinones and the objectives of the present work. 
PYRROLO[2,1-c][1,4]BENZODIAZEPINES  
 Cancer is a group of diseases characterized by uncontrolled growth or spread 
of abnormal cells. Since it involves the conversion of any normal cells to a cancerous 
cell exhibiting tandem replication and cell divisions at much faster rate in comparison 
to the normal cells and thus provides a potential target area for the development of 
chemotherapeutic agents. It is now clear that chemotherapy’s most effective role in 
solid tumors is as an adjuvant to initial therapy by surgical or radiotherapeutic 
procedures. Chemotherapy becomes critical to effective treatment because only 
systemic therapy can attack micrometastases. These agents can be categorized into 
functional sub groups, alkylating agents, antimetabolites, antibiotics, and antimitotics. 
The pyrrolo[2,1-c][1,4]-benzodiazepines (PBDs) belonging to the class of DNA-
interactive antitumor antibiotics have the potential as regulators of gene expression 
with possible therapeutic application in the treatment of genetic disorders including 
cancer. The first PBD antitumor antibiotic anthramycin (Figure 1) has been described 
by Leimgruber coworkers about 40 years back and since then a number of compounds 
have been developed based on PBD ring system leading to DNA binding ligands. 
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Figure 1. Chemical structures of anthramycin and tomaymycin 
Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of potent naturally 
occurring low molecular weight antitumor antibiotics originally isolated from various 
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Streptomyces species. Their common interaction with DNA has been extensively 
investigated and it is considered unique since they bind within the minor groove of 
DNA forming a covalent aminal bond between the C11-position of the central B-ring 
and the N2 amino group of guanine base as depicted in Figure 2. A number of 
naturally occurring and synthetic compounds based on PBD ring system, such as 
anthramycin, tomaymycin, DC-81 and its dimers (presently, one of the dimer SJG-136 
is under clinical evaluation), have shown varying degrees of DNA binding affinity 
and anticancer activity. 
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Figure 2. Formation covalent bond between PBD and DNA 
Combretastatin A-4 (CA-4, 1, Figure 3), a natural product isolated by Pettit and 
co-workers from the bark of South African tree Combretum caffrum, exhibits 
cytotoxicity against a broad range of human cancer cell lines as well as multidrug 
resistant cell lines by inhibiting tubulin polymerization and binding to the colchicine 
binding site. A water soluble disodium phosphate prodrug (CA-4P) of CA-4 and 
AVE8062, are currently under clinical trials for the treatment of cancer.  
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Figure 3. Chemical structures of Combretastatin A-4 derivatives 
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In recent years there has been an increasing interest in the chemistry of 
quinazolinones because of their wide range of biological significance. Among the 
various classes of quinazolinones, 2,3-dihydro/2-styryl quinazolinone and  2-methyl 
quinazolinone derivatives (Figure 4) exhibited anticancer activity by inhibitory effects 
on tubulin polymerization or inhibition the DNA repair enzyme poly(ADP-
ribose)polymerase (PARP). 
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Figure 4. Chemical structures of various quinazolinones 
 
 
Chemotherapy is often the treatment of choice for many types of cancer as a 
result the search for newer chemotherapeutic agents still plays a major role in the fight 
against cancer. In recent years there has been increasing interest in the design of 
conjugate molecules that could act in a specific manner on more than one target. The 
development of such conjugates lowers the risk of drug-drug interaction in 
comparison to cocktails but could also enhance the efficacy as well as improve the 
safety aspects in relation to the drugs that interact on a single target. Several conjugate 
compounds, in which a known antitumor compound or some simple active moiety 
tethered to PBD, have been designed, synthesized and evaluated for their biological 
activity. Recently, Wang and co-workers have synthesized indole-PBD conjugates as 
potential antitumor agents and a correlation between antitumor activity and apoptosis 
has been well explained. More recently, we have also reported some of the PBD 
conjugates that demonstrate potent apoptotic activity through mitochondrial-
mediated pathway. 
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In continuation of these efforts, substituted diaryl ether derivatives were linked 
to the C8-position of the PBD scaffold (DC-81) through the stable alkane spacer and 
also by incorporating a piperazine moiety in spacer linker. This led to a new library of 
PBD conjugates that were evaluated for their anticancer potential. Therefore this 
chapter describes the synthesis, DNA-binding ability and anticancer activity of some 
new PBD conjugates.  
SYNTHESIS OF DIARYL ETHER LINKED PYRROLOBENZODIAZEPINE CONJUGATES 
Synthesis of the PBD subunit precursors (11, 12) is carried out by employing the 
commercially available vanillin (1) as the starting material. Oxidation of vanillin in the 
presence of sulphamic acid and sodium chlorite to form the corresponding carboxylic 
acid (2) and followed by acid-catalyzed esterification with methanol provided methyl 
benzoate (3) in quantitative yield. This is followed by benzylation, nitration and basic 
hydrolysis to provide 4-benzyloxy-5-methoxy-2-nitrobenzoic acid (6). Later this has 
been coupled to L-proline methyl ester in the presence of triethylamine to afford the 
compound 7, which upon reduction with DIBAL-H produces the corresponding 
aldehyde 8. This product upon protection with EtSH/TMSCl gives compound 9, 
which on debenzylation with BF3.OEt2/EtSH provides the hydroxyl intermediate 
compound 10, which upon etherification by dibromoalkane provide 11, which upon 
reduction with SnCl2·2H2O provides 12 (Scheme 1). 
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Scheme 1: Reagents and conditions: (i) NH2SO3H, NaClO2, H2O, rt, 2 h; (ii) H2SO4, MeOH, 
reflux, 4 h; (iii) benzylbromide, K2CO3, acetone, reflux, 24 h; (iv) SnCl4, fuming HNO3, CH2Cl2, 
5 min, -25 oC; (v) 2N LiOH, MeOH, H2O, THF (1:1:3), rt, 12 h; (vi) SOCl2, C6H6, L-proline 
methylester hydrochloride, THF-H2O, 1-2 h, rt; (vii) DIBAL-H, CH2Cl2, 1-1.3 h, -78 oC; (viii) 
EtSH, TMSCl, CH2Cl2, 8-12 h, rt; (ix) BF3.OEt2, EtSH, CHCl3, rt, 8 h; (x) dibromoalkane, K2CO3, 
acetone, reflux, 24 h; (xi) SnCl2·2H2O, MeOH, reflux, 4 h. 
The synthesis of substituted diaryl ether precursors (19a–c, 20a–c, 25a–c and 26a–
c) is outlined in Scheme 2. Compounds 3-fluoro-4-nitrophenol (13) and 4-fluoro-3-
nitrophenol (14) upon benzylation to obtain 15 and 16 which upon substitution with 
substituted phenols in dry DMF gave the compounds 17a–c and 18a–c, which on 
debenzylation gives 19a–c and 20a–c respectively. Compounds 17a–c and 18a–c on 
reduction with SnCl2·2H2O gives amino compound of 21a–c and 22a–c, which on 
treating with HI and DMSO gives the iodo compound of 23a–c and 24a–c. Compound 
23a–c and 24a–c on debezylation gives the compounds of 25a–c and 26ac 
respectively. 
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19c, 25c: R1, R2, R3 = OCH3, 4OH
20a, 26a: R1, R3 = H, R2 = OCH3, 3OH
20b, 26b: R1, R2 = OCH3, R
3 = H, 3OH
20c, 26c: R1, R2, R3 = OCH3, 3OH  
Scheme 2: Reagents and conditions: (i) BnBr, dry acetone, reflux, 10-12 h; (ii) substituted phenol, 
Cs2CO3, dry DMF, 70 oC, 10-12 h; (iii) TiCl4, dry DCM, 0 oC, 30 min.; (iv) SnCl2·2H2O, MeOH, 
reflux, 3-4 h; (v) HI, DMSO, CuI, rt, 30 min. 
The synthesis of piperazine containing diaryl ether precursors (30a–c) is 
outlined in Scheme 3. Compound 28 is obtained by coupling of commercially available 
4-chloro-3-nitrobenzoic acid (27) with tert-butyl piperazine-1-carboxylate. Compound 
28 upon substitution with substituted phenols in dry DMF gives the compound 29a–c, 
which on deprotection gives compound 30a–c (Scheme 3). 
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Scheme 3: Reagents and conditions: (i) (a) SOCl2, C6H6, DMF (cat.); (b) tert-butyl piperazine-1-
carboxylate, Et3N, dry THF, 0 oC, 1-2 h; (ii) substituted phenol, Cs2CO3, dry DMF, 70 oC, 10-12 
h; (iii) CF3COOH, DCM, 0 oC, 10-12 h. 
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Synthesis of C8-linked diaryl ether-PBD conjugates (33a–f, 36a–f, 39a–c, 41a–c, 
43a–c and 45a–c) has been carried out from the (2S)-N-{4-[5-bromopentyloxy]-5-
methoxy-2-nitrobenzoyl}pyrrolidine-2-carboxaldehyde diethyl thioacetal (11) and 
(2S)-N-{4-[5-bromopentyloxy]-5-methoxy-2-aminobenzoyl}pyrrolidine-2-carboxalde-
hydediethyl thioacetal (12), these upon etherification with the phenolic diethyl ether 
precursors (17a–c, 18a–c, 25a–c, 26a–c and 30a–c) using K2CO3 in acetone provided the 
corresponding nitro thioacetals (31a–f, 34a–f and 37a–c) and amino thioacetals (40a–c, 
42a–c and 44a–c). These nitro thioacetals 31a–f, 34a–f and 37a–c are reduced to the 
amino thioacetals 32a–f, 35a–f and 38a–c by employing SnCl2·2H2O in refluxing 
methanol and then cyclized by treatment with HgCl2 and CaCO3 in MeCN-H2O to 
yield the target products 33a–f, 36a–f, 39a–c, 41a–c, 43a–c and 45a–c (Schemes 47). 
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Scheme 4: Reagents & conditions: (i) 17a–c and 25a–c, K2CO3, dry acetone, reflux, 24 h; (ii) 18a–c 
and 26a–c, K2CO3, dry acetone, reflux, 24 h; (iii) SnCl2·2H2O, MeOH, reflux, 3-4 h; (iv) HgCl2, 
CaCO3, CH3CN-H2O,  (4:1), rt, 12 h. 
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Scheme 5: Reagents & conditions: (i) 30ac, K2CO3, dry acetone, reflux, 24 h; (ii)  SnCl2.2H2O, 
MeOH, reflux, 3-4 h; (iii) HgCl2, CaCO3, CH3CN-H2O,  (4:1), rt, 12 h. 
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Scheme 6: Reagents & conditions: (i) 17ac and 18c, K2CO3, dry DMF, rt, 12 h; (ii) HgCl2, 
CaCO3, CH3CN-H2O,  (4:1), rt, 12 h. 
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Scheme 7: Reagents & conditions: (i) 30ac, K2CO3, dry DMF, rt, 12 h; (ii) HgCl2, CaCO3, 
CH3CN-H2O,  (4:1), rt, 12 h. 
 
Thermal denaturation studies showed that these conjugates exhibit higher DNA 
binding affinity than the naturally occurring DC-81. All these PBD conjugates 25a–x 
and 26a–h showed significant anticancer activity, with GI50 values ranging from 0.01 
to 3.41 , whereas the positive controls adriamycin and DC-81 demonstrated the 
GI50 in the range of 0.10 to 7.25 M and 0.10 to 2.37 M, respectively (Patent filed 
0390/DEL/11 (India), PCT/IB2011/000670, manuscript accepted in Anri-cancer Agents 
Med. Chem.).  
 
 
This chapter describes the design, synthesis, and biological evaluation of 
tetrazole linked isoxazoline/cinnamides as anticancer agents and tubulin 
polymerarization inhibitors. Tubulin is a heterodimeric protein consisting of α and β 
subunits. During cellular division upon binding of GTP, tubulin polymerizes into 
microtubules. This formation of microtubule is essential for chromosome separation 
and formation of two daughter cells. Hence, microtubules are the important targets for 
the development of new potential anticancer therapeutics. When ligands that interact 
with tubulin are present, a reduction in cellular division is observed and shows 
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anticancer activity. Tubulin having colchicine binding site and if any ligand binds to 
this site prevents the tubulin polymerization. Colchicine and combretastatin-A-4 (CA-
4) are the good examples as tubulin binding agents. Combretastatin A-4 is a naturally 
occurring stilbene and isolated from the African willow tree (Combretum caffrum). CA-
4 shows interesting anticancer potential due to its inhibition of tubulin polymerization 
property. It strongly binds to the colchicine site of tubulin thus preventing tubulin 
polymerization and causes antimitotic effect. The cis configuration at olefinic bidge is 
essential for biological activity, unfortunately this cis olefin is converted into 
thermodynamically stable trans form during storage and metabolism, which 
eventually leads to loss of cytotoxicity as well as tubulin polymerization inhibition. To 
overcome this problem, many heterocyclic five membered rings (thiazole, oxazole, 
imidazole, triazole, tetrazole etc.) have incorporated to retain cis configuration at the 
olefinic bridge.  
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Figure 1. Potential inhibitors of tubulin polymerization 
SYNTHESIS OF TETRAZOLE LINLED ISOXAZOLINES 
The synthesis of tetrazole linked isoxazoline derivatives (15a–l) was carried out 
by using the commercially available aldehydes (1a–k, 3) as the starting material. 
Reaction of these aldehydes (1a–k) with hydroxylamine in a MeOH/H2O (3:1) 
solution produced the corresponding oximes (2a–k) in high yields. 4-Hydroxy-3-
nitrobenzaldehyde (3) was benzylated with benzyl bromide to afford the compound 4, 
which is oxidized to the acid (5) by using oxone. Later this acid (5) was coupled with 
3,4,5-trimethoxyaniline to afford the amide compound (6). Further, amide (6) was 
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converted into thioamide (7) by using Lawesson’s reagent followed by conversion to 
its amidrazide (8) by using hydrazine hydrate, this was cyclized in the presence of 
NaNO2 and acetic acid to afford the tetrazole (9) in quantitative yield. Later this 
tetrazole (9) was debenzylated with TiCl4 to provide the nitro phenolic compound 
(10), which upon etherification with allyl bromide using K2CO3 and DMF to provide 
the nitro allyloxy compound 11. This was then coupled to different oximes (2a–k) to 
provide the corresponding tetrazole linked isoxazolines (12a–k). The nitro group of 
tetrazole (11 and 12a–k) was reduced to the amine with Zn and acetic acid to afford 
the amino allyloxy compound (14) and the desired tetrazole-isoxazoline hydrids (15a–
k) as shown in Scheme 1. This amino allyloxy compound (14) was coupled to the 
oxime (2g) to provide the desired tetrazole linked isoxazoline (15l) as shown in 
Scheme 2. 
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Scheme 1. Reagents & conditions: (i) NH2OH·HCl, NaHCO3, methanol, water, 0 oC to rt, 3h; (ii) 
BnBr, K2CO3, DMF, rt, 12h; (iii) Oxone, DMF, rt, 10h; (iv) SOCl2, DMF, C6H6, 3,4,5-
   SYNOPSIS 
 
XIII 
trimethoxyaniline, TEA, dry THF, 0 oC to rt, 2h; (v) Lawesson's reagent, dry toluene, reflux, 
4h; (vi) NH2NH2·H2O, DCM, EtOH, rt, 6h; (vii) NaNO2, AcOH, rt, 4h; (viii) TiCl4, DCM, 0 oC, 
30 min; (ix) Allyl bromide, K2CO3, DMF, 0 oC to rt, 10h; (x) 2a-k, NaOCl, DCM, TEA, 0 oC to rt, 
12h; (xi) TBAF, dry THF, rt, 30 min; (xii) Zn dust, AcOH, rt, 3h. 
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Scheme 2. Reagents & conditions: (i) Zn dust, AcOH, rt, 3h; (ii) 2g, NaOCl, DCM, TEA, 0 oC to 
rt, 12h. 
SYNTHESIS OF TETRAZOLE LINKED CINNAMIDES 
The synthesis of tetrazole linked cinnamide derivatives (24a–v) was carried out 
by using the commercially available 1,2-difluoro-4-nitrobenzene (16) as shown in 
Scheme 3. Compound 16 on nucleophilic substitution with tert-butyl piperazine-1-
carboxylate by using K2CO3 forms N-Boc protected nitro compound (17) in high 
yields. This on reduction with Zn/CH3COOH forms the amino compound (18), which 
on coupled with 3,4,5-trimethoxybenzoyl chloride to afford the amide compound (19) 
in good yields. Later, amide was converted into thioamide (20) by using Lawesson’s 
reagent followed by conversion to its amidrazide (21) by using hydrazine hydrate. 
This amidrazide was cyclized by using NaNO2 in acetic acid to afford the N-Boc 
protected tetrazole (22) in quantitative yields, this on deprotection with tirfluoro acetic 
acid to afford secondary amino compound (23). Further this on coupled with different 
cinnamic acids to provide the desired tetrazole linked cinnamide hybrids (24a–v) in 
good yields. 
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Scheme 3. Reagents & conditions: (i) tert-Butyl piperazine-1-carboxylate, K2CO3, DMSO, 70 oC, 
10h; (ii) SnCl2·2H2O, MeOH, reflux, 4h; (iii) 3,4,5-Trimethoxybenzoyl chloride, TEA, dry THF, 
0 oC, 2h; (iv) Lawesson's reagent, dry toluene, reflux, 4h; (v) NH2NH2·H2O, DCM, EtOH, rt, 
6h; (vi) NaNO2, AcOH, rt, 4h; (vii) TFA, DCM, 0 oC to rt, 12h; (viii) Substituted cinnamic acids, 
EDCI, HOBt, DCM, rt, 6h. 
BIOLOGICAL ACTIVITY OF TETRAZOLE LINKED ISOXAZOLINE/CINNAMIDE HYBRIDS 
A new series of tetrazole linked isoxazoline/cinnamide hybrids were 
synthesized and evaluated for their anticancer and inhibition of tubulin 
polymerization activities. These compounds exhibited significant anticancer activity 
with IC50 values ranging from 0.86 to 26.80 µM. The FACS analysis has shown more 
population in G2/M phase, which is suggestive of G2/M cell cycle arrest. Further 
these compounds (15h, 15i) induce apoptotic cell death by inhibition of tubulin 
polymerization leading to cell cycle arrest at G2/M phase of the cell cycle followed by 
caspase-3 activity (Accepted in Med.Chem.Comm.).  
 
 
In continuation to our efforts on the design of new anticancer agents, a series of 
quinazoline linked chalcones and 2-vinylfuryl quinazolinone derivatives have been 
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synthesized and evaluated for their anticancer activity against 4 human cancer cell 
lines.  
SYNTHESIS OF QUINAZOLINONE LINKED CHALCONES  
The quinazolinone linked chalcone derivatives (8a–v) are synthesized from the 
commertially available substituted antranilic acids (1a–c) as outlined in Schemes 1. 
The first synthetic step involved the condensation of anthranilic acids (1a–c) with 
acetic anhydride to afford the corresponding benzoxazinones (2a–c) respectively in 
quantitative yields. Later these benzoxazinones (2a–c) was coupled to 3-amino 
acetophenone to provide the quinazolinone compounds (3a–c). The 6-hydroxy 
quinazolinone (3c) on methylation gives the 6-methoxy quinazolinone (3d). These 
quinazolinones (3a–d) undergoes condensation reaction with substituted 
benzaldehydes in presence of Ba(OH)2 to afford the desired quinazolinone linked 
chalcones (8a–t) in good yields. The quinazolinone linked indolylchalcone (8u) was 
obtained by reacting quinazolinone (3a) with indole-3-aldehyde in presence of base. 
The other types of quinazolinone linked chalcone (8v) was obtained by the 
condensation of 3,4,5-trimethoxy acetophenone (4) with 3-nitro benzaldehyde (5) in 
presence of base to give the nitro chalcone (6), this on reduction with Zn/AcOH 
provided the amino compound (7). Further, this amino compound undergoes 
insertion reaction with benzoxazinone (2a) to afford the quinazolinone linked 
chalcone (8v) (Scheme 2). 
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Scheme 1. Reagents & conditions: (i) (CH3CO)2O, 150 oC, 30 min.; (ii) 3-aminoacetophenone, 
AcOH, reflux, 4 h; (iii) NaOH, EtOH, rt, 12 h. 
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Scheme 2. Reagents & conditions: (i) NaOH, EtOH, rt, 4 h; (ii) SnCl2.2H2O, MeOH, reflux, 4 h; 
(iii) AcOH, reflux, 4 h. 
A new class of chalcone linked quinazolinone conjugates have been synthesized 
and evaluated for their in vitro anticancer activities against four human cancer cell 
lines. All the compounds showed significant anticancer potency against the tested 
cancer cell lines with IC50 values in the range of 0.017 to 24.82 µM, however some of 
the compounds (8p, 8v) exhibited significant anticancer potency with IC50 values in 
the range of 0.017 to 4.60 µM (Manuscript under preparation).  
